Thermo Fisher (TMO) to Sell Microbiology Diagnostics Business to Private Equity Firm Astorg for $1.075 Billion
A Sign of Portfolio Restructuring
Thermo Fisher Scientific (TMO) has agreed to sell its Microbiology Diagnostics business to European private equity firm Astorg for a total of $1.075 billion (approximately $1.4 billion). This transaction marks the realization of rumors circulating in the industry since last year about the potential divestiture of this business unit. It is interpreted as a strategic decision by Thermo Fisher to streamline its portfolio by divesting mature, lower-margin diagnostic assets. Thermo Fisher plans to reinvest the proceeds into its high-growth, high-value Genomics and Cell & Gene Therapy R&D segments. This aligns with the trend of large healthcare companies restructuring their businesses to solidify their leadership in biopharmaceutical equipment and precision diagnostics.
Astorg's Strategy to Build a Diagnostics Platform
Astorg, which is acquiring the Microbiology Diagnostics business, has announced plans to develop it into an independent, global diagnostics platform. The acquired business is a leading global provider of antimicrobial susceptibility testing (AST) and culture media solutions, based on the Remel and Oxoid brands. With 13 manufacturing and R&D sites and approximately 2,400 employees worldwide, Astorg aims to improve operational efficiency and maximize value through aggressive M&A activities. The business is expected to benefit from the increasing complexity of infectious diseases and the strengthening of pharmaceutical and food regulations, making it a stable cash cow.
Financial Impact and Shareholder Value
The divestiture will have a slight negative impact on Thermo Fisher's short-term profitability, with adjusted earnings per share (EPS) expected to be diluted by approximately $0.15 in the first year following the completion of the transaction. However, by selling the Specialty Diagnostics business, which generated $645 million in annual revenue in 2025, Thermo Fisher has improved its capital productivity and further strengthened its balance sheet. The $1 billion in proceeds will be used to repay debt incurred from recent acquisitions, such as the $9 billion acquisition of Clario, a clinical data company, and to provide flexibility for share buybacks and investments in next-generation modality equipment.
Changes in the Competitive Landscape of the Global Diagnostics Market
The global microbiology diagnostics and antimicrobial susceptibility testing (AST) market is currently led by bioMérieux (BIM) and Becton Dickinson (BDX). With Thermo Fisher's business being spun off as an independent platform backed by private equity, competition for market share with these existing leaders is expected to intensify. Healthcare providers and pharmaceutical companies are accelerating the adoption of rapid diagnostic devices incorporating artificial intelligence (AI) and automation, and Astorg is expected to challenge competitors such as bioMérieux's VITEK system by upgrading the technology of its new platform.
Thermo Fisher's (TMO) sale of its microbiology diagnostics business is a strategic move to unlock value from mature assets and optimize capital allocation for investments in next-generation bio sectors. The divested business, generating $645 million in annual revenue, comprises marketed diagnostic solutions. Under the support of private equity firm Astorg, the independent platform is poised to disrupt the global antimicrobial susceptibility testing (AST) market, estimated at $4 billion to $5 billion. The new platform is expected to strengthen investments in AI-based automation solutions to compete with existing leaders such as bioMérieux (BIM) and Becton Dickinson (BDX). While the transaction will result in a $0.15 dilution of adjusted EPS in the first year, it is expected to improve capital structure and enable Thermo Fisher to focus on high-growth core portfolios in the medium to long term, including debt repayment from the $9 billion Clario acquisition. From the perspective of research and diagnostics professionals, the platform spin-off is expected to have a medium- to long-term impact by expanding research infrastructure centered around the global 13 manufacturing and R&D sites and accelerating clinical decision-making.